3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
3
Neoplasms
3
Lymphoma
3
Leukemia
3
Infections
3
Paraneoplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Bacterial Infections
1
Agammaglobulinemia
1
Interventions
venetoclax
30
obinutuzumab
22
acalabrutinib
20
Specimen Handling
19
ibrutinib
16
Cyclophosphamide
15
Biopsy
15
pirtobrutinib
14
zanubrutinib
12
fludarabine
12
Rituximab
12
Magnetic Resonance Spectroscopy
10
Bendamustine Hydrochloride
5
Stem Cell Transplantation
4
Blood Component Removal
4
ARQ531
4
idelalisib
3
fludarabine phosphate
3
Whole-Body Irradiation
3
Mycophenolic Acid
3
tocilizumab
2
polatuzumab vedotin
2
Watchful Waiting
2
Sirolimus
2
Prednisone
2
Pneumococcal Vaccines
2
Lisaftoclax
2
Leukapheresis
2
Hematopoietic Stem Cell Transplantation
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
gamma-Globulins
×
Clear all
NCT05645107
2026-04-13
EXCELL
Grifols Therapeutics LLC
Phase 3
Recruiting
386 enrolled